Nucleic Acids, Protein Synthesis, and Molecular Genetics
Molecular Basis of the Soluble and Membrane-bound Forms of the Murine Leukemia Inhibitory Factor Receptor α-Chain: EXPRESSION IN NORMAL, GESTATING, AND LEUKEMIA INHIBITORY FACTOR NULLIZYGOUS MICE (∗)

https://doi.org/10.1074/jbc.271.10.5495Get rights and content
Under a Creative Commons license
open access

The murine leukemia inhibitory factor receptor α-chain (mLIFR) exists in a membrane-bound and a soluble form. The two major classes of mRNA transcript correspond to either the soluble or membrane-bound form of the mLIFR. In this study we have identified a complex and heterogeneous pattern of expression of mRNA transcripts for this receptor in normal mouse tissues and cell lines. In order to understand the molecular basis of these transcripts, genomic clones encompassing the region of divergence from the soluble to the membrane-bound form of the receptor were isolated. cDNAs encoding the membrane-bound form of the mLIFR were generated by an alternative splicing event where an exon that is specific to the soluble mLIFR was skipped. The membrane-bound form of the mLIFR was heterogeneously polyadenylated with at least five different sites of polyadenylation. The mRNA transcript encoding the soluble form of the mLIFR contained a region highly homologous to a murine B2 repetitive element, thus providing a possible explanation for the genesis of this transcript. The different forms of the mLIFR were analyzed in a wide range of mouse tissues in pseudopregnant mice and in mice at various stages of pregnancy. Only liver, placenta, and uterus showed an increase in the levels of mLIFR mRNA expression during pregnancy, indicating an important role for the LIFR in this process. However, somewhat surprisingly, there was no detectable difference in mLIFR mRNA levels or levels of soluble protein in leukemia inhibitory factor nullizygous mice when compared with normal mice.

Cited by (0)

This work was supported by the National Health and Medical Research Council (Canberra), the Anti-Cancer Council of Victoria, AMRAD Corporation (Melbourne), the J. D. and L. Harris Trust Fund, the Philip Bushell Trust, National Institutes of Health Grant CA22556, and the Australian Government Cooperative Research Centres scheme. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Current address: Ludwig Institute for Cancer Research, 91 Riding Horse St., London WIP 8BT, United Kingdom.